View Future GrowthPentixapharm Holding 과거 순이익 실적과거 기준 점검 0/6Pentixapharm Holding의 수입은 연평균 -36.3%의 비율로 감소해 온 반면, Medical Equipment 산업의 수입은 연간 16.2% 증가했습니다.핵심 정보-36.28%순이익 성장률25.26%주당순이익(EPS) 성장률Medical Equipment 산업 성장률8.90%매출 성장률n/a자기자본이익률-52.80%순이익률-6,211.57%최근 순이익 업데이트30 Jun 2026최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jul 29+ 1 more updatePentixapharm Holding AG has completed a Follow-on Equity Offering in the amount of €20.387392 million.Pentixapharm Holding AG has completed a Follow-on Equity Offering in the amount of €20.387392 million. Security Name: Ordinary Bearer Shares Security Type: Common Stock Securities Offered: 9,096,771 Price\Range: €1.85 Security Name: Ordinary Bearer Shares Security Type: Common Stock Securities Offered: 1,923,441 Price\Range: €1.85 Transaction Features: Rights Offering; Subsequent Direct Listing공고 • Jul 11Pentixapharm Holding AG Receives FDA Fast Track Designation For Phase 3 Diagnostic Candidate [68Ga]Ga-Pentixafor In Primary AldosteronismPentixapharm Holding AG received notice from the U.S. Food and Drug Administration (FDA) that Fast Track designation has been granted to its development candidate [68Ga]Ga-PentixaFor for the diagnosis of patients with hypertension and underlying primary aldosteronism. In its notification, the FDA determined that Pentixapharm's request meets the criteria for Fast Track designation and that [68Ga]Ga-PentixaFor is accordingly designated as a Fast Track product for the diagnostic subtyping of adult patients with confirmed primary aldosteronism. Fast Track designation is intended to facilitate the development and review of products that address serious conditions and have the potential to fill an unmet medical need. It provides opportunities for more frequent interaction with the FDA during development and may support a more efficient regulatory review process if the relevant criteria are met. The practical benefit of Fast Track designation lies above all in closer and more frequent interaction with the FDA, allowing development and submission questions to be clarified early and the regulatory process to be prepared efficiently. The FDA's specific designation relates to the diagnostic subtyping of adult patients with already confirmed primary aldosteronism, precisely the clinical decision point at which physicians must distinguish between potential surgical treatment and long-term medical therapy. The designation follows Pentixapharm's recent announcement that the Investigational New Drug (IND) application for the U.S. Phase 3 PANDA study of [68Ga]Ga-PentixaFor became effective following the FDA's 30-day review period, with the FDA allowing the study to proceed (“Study May Proceed”). [68Ga]Ga-PentixaFor addresses a central diagnostic bottleneck in primary aldosteronism and hypertension: non-invasive subtyping to guide the treatment decision between surgery and chronic medical therapy. Pentixapharm is preparing to initiate its pivotal Phase 3 PANDA study in the United States. PANDA is designed to evaluate [68Ga]Ga-PentixaFor PET/CT as a non-invasive imaging approach to help identify patients with unilateral primary aldosteronism. This distinction is clinically important because unilateral disease may be treated with surgical removal of the affected adrenal gland in selected patients, while bilateral disease generally requires long-term medical therapy. Primary aldosteronism is one of the most common and substantially underdiagnosed causes of secondary hypertension. The condition occurs when one or both adrenal glands produce too much aldosterone, a hormone that can drive high blood pressure and increase cardiovascular risk. For patients, the key treatment question is not only whether primary aldosteronism is present, but whether excess aldosterone production is coming from one adrenal gland or both. This makes accurate subtyping central to treatment selection and creates a major diagnostic bottleneck in the current care pathway. [68Ga]Ga-PentixaFor is designed to target CXCR4, a biological receptor shown to be strongly expressed in aldosterone-producing adrenal lesions. By visualizing CXCR4 expression with PET/CT, Pentixapharm aims to support a more precise and patient-friendly diagnostic pathway that can help physicians guide patients toward the appropriate treatment option. [68Ga]Ga-PentixaFor is a novel gallium-68-labeled radiodiagnostic designed to selectively target and visualize the chemokine receptor CXCR4 using high-resolution PET/CT imaging. Clinical experience with [68Ga]Ga-PentixaFor PET/CT in more than 2,000 patients across different indications has demonstrated its ability to non-invasively image CXCR4 expression in vivo. Pentixapharm is evaluating this established CXCR4 imaging approach in primary aldosteronism, where molecular characterization of adrenal lesions may help address limitations of conventional anatomical imaging. Recent research has shown strong CXCR4 overexpression in aldosterone-producing adrenal tumors, supporting its potential relevance for identifying unilateral disease. Primary aldosteronism (PA) is increasingly recognized as one of the most common and significantly underdiagnosed endocrine disorders worldwide and a leading cause of secondary hypertension. Recent international and Endocrine Society guidelines have expanded recommendations for PA screening, reflecting growing evidence that the disease may affect approximately 5–10% of all patients with hypertension and up to 20–30% of those with treatment-resistant hypertension. Given the high prevalence of hypertension in the United States and globally, even modest improvements in PA detection and subtyping could translate into a meaningfully larger diagnosed and treatment-directed patient population. As awareness, screening, and targeted treatment options continue to advance, the diagnostic landscape for PA is undergoing a fundamental transformation. This shift has the potential to expand the addressable patient population from a highly selected subgroup to millions of patients globally, creating a substantial opportunity for innovative diagnostic approaches aimed at improving disease detection, patient stratification, and treatment selection.공고 • Jul 03Pentixapharm Holding AG has filed a Follow-on Equity Offering in the amount of €20.387392 million.Pentixapharm Holding AG has filed a Follow-on Equity Offering in the amount of €20.387392 million. Security Name: Ordinary Bearer Shares Security Type: Common Stock Securities Offered: 11,020,212 Price\Range: €1.85 Transaction Features: Rights Offering매출 및 비용 세부 내역Pentixapharm Holding가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:PTPD.F 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비30 Jun 260-157031 Mar 260-167031 Dec 251-177030 Sep 252-266030 Jun 25-1-203031 Mar 251-163001 Jan 252-132030 Jun 244-51031 Mar 247-82031 Dec 237-82031 Dec 224-21031 Dec 213-210양질의 수익: PTPD.F 은(는) 현재 수익성이 없습니다.이익 마진 증가: PTPD.F는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: PTPD.F은 수익성이 없으며 지난 5년 동안 손실이 연평균 36.3% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 PTPD.F의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: PTPD.F은 수익성이 없어 지난 해 수익 성장률을 Medical Equipment 업계(15.6%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: PTPD.F는 현재 수익성이 없으므로 자본 수익률이 음수(-52.8%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YHealthcare 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/10 21:05종가2026/06/22 00:00수익2026/06/30연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Pentixapharm Holding AG는 2명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Roger BeckerBankM AGSimon KellerNuWays AG
공고 • Jul 29+ 1 more updatePentixapharm Holding AG has completed a Follow-on Equity Offering in the amount of €20.387392 million.Pentixapharm Holding AG has completed a Follow-on Equity Offering in the amount of €20.387392 million. Security Name: Ordinary Bearer Shares Security Type: Common Stock Securities Offered: 9,096,771 Price\Range: €1.85 Security Name: Ordinary Bearer Shares Security Type: Common Stock Securities Offered: 1,923,441 Price\Range: €1.85 Transaction Features: Rights Offering; Subsequent Direct Listing
공고 • Jul 11Pentixapharm Holding AG Receives FDA Fast Track Designation For Phase 3 Diagnostic Candidate [68Ga]Ga-Pentixafor In Primary AldosteronismPentixapharm Holding AG received notice from the U.S. Food and Drug Administration (FDA) that Fast Track designation has been granted to its development candidate [68Ga]Ga-PentixaFor for the diagnosis of patients with hypertension and underlying primary aldosteronism. In its notification, the FDA determined that Pentixapharm's request meets the criteria for Fast Track designation and that [68Ga]Ga-PentixaFor is accordingly designated as a Fast Track product for the diagnostic subtyping of adult patients with confirmed primary aldosteronism. Fast Track designation is intended to facilitate the development and review of products that address serious conditions and have the potential to fill an unmet medical need. It provides opportunities for more frequent interaction with the FDA during development and may support a more efficient regulatory review process if the relevant criteria are met. The practical benefit of Fast Track designation lies above all in closer and more frequent interaction with the FDA, allowing development and submission questions to be clarified early and the regulatory process to be prepared efficiently. The FDA's specific designation relates to the diagnostic subtyping of adult patients with already confirmed primary aldosteronism, precisely the clinical decision point at which physicians must distinguish between potential surgical treatment and long-term medical therapy. The designation follows Pentixapharm's recent announcement that the Investigational New Drug (IND) application for the U.S. Phase 3 PANDA study of [68Ga]Ga-PentixaFor became effective following the FDA's 30-day review period, with the FDA allowing the study to proceed (“Study May Proceed”). [68Ga]Ga-PentixaFor addresses a central diagnostic bottleneck in primary aldosteronism and hypertension: non-invasive subtyping to guide the treatment decision between surgery and chronic medical therapy. Pentixapharm is preparing to initiate its pivotal Phase 3 PANDA study in the United States. PANDA is designed to evaluate [68Ga]Ga-PentixaFor PET/CT as a non-invasive imaging approach to help identify patients with unilateral primary aldosteronism. This distinction is clinically important because unilateral disease may be treated with surgical removal of the affected adrenal gland in selected patients, while bilateral disease generally requires long-term medical therapy. Primary aldosteronism is one of the most common and substantially underdiagnosed causes of secondary hypertension. The condition occurs when one or both adrenal glands produce too much aldosterone, a hormone that can drive high blood pressure and increase cardiovascular risk. For patients, the key treatment question is not only whether primary aldosteronism is present, but whether excess aldosterone production is coming from one adrenal gland or both. This makes accurate subtyping central to treatment selection and creates a major diagnostic bottleneck in the current care pathway. [68Ga]Ga-PentixaFor is designed to target CXCR4, a biological receptor shown to be strongly expressed in aldosterone-producing adrenal lesions. By visualizing CXCR4 expression with PET/CT, Pentixapharm aims to support a more precise and patient-friendly diagnostic pathway that can help physicians guide patients toward the appropriate treatment option. [68Ga]Ga-PentixaFor is a novel gallium-68-labeled radiodiagnostic designed to selectively target and visualize the chemokine receptor CXCR4 using high-resolution PET/CT imaging. Clinical experience with [68Ga]Ga-PentixaFor PET/CT in more than 2,000 patients across different indications has demonstrated its ability to non-invasively image CXCR4 expression in vivo. Pentixapharm is evaluating this established CXCR4 imaging approach in primary aldosteronism, where molecular characterization of adrenal lesions may help address limitations of conventional anatomical imaging. Recent research has shown strong CXCR4 overexpression in aldosterone-producing adrenal tumors, supporting its potential relevance for identifying unilateral disease. Primary aldosteronism (PA) is increasingly recognized as one of the most common and significantly underdiagnosed endocrine disorders worldwide and a leading cause of secondary hypertension. Recent international and Endocrine Society guidelines have expanded recommendations for PA screening, reflecting growing evidence that the disease may affect approximately 5–10% of all patients with hypertension and up to 20–30% of those with treatment-resistant hypertension. Given the high prevalence of hypertension in the United States and globally, even modest improvements in PA detection and subtyping could translate into a meaningfully larger diagnosed and treatment-directed patient population. As awareness, screening, and targeted treatment options continue to advance, the diagnostic landscape for PA is undergoing a fundamental transformation. This shift has the potential to expand the addressable patient population from a highly selected subgroup to millions of patients globally, creating a substantial opportunity for innovative diagnostic approaches aimed at improving disease detection, patient stratification, and treatment selection.
공고 • Jul 03Pentixapharm Holding AG has filed a Follow-on Equity Offering in the amount of €20.387392 million.Pentixapharm Holding AG has filed a Follow-on Equity Offering in the amount of €20.387392 million. Security Name: Ordinary Bearer Shares Security Type: Common Stock Securities Offered: 11,020,212 Price\Range: €1.85 Transaction Features: Rights Offering